Unicycive Therapeutics Inc. has released a corporate presentation highlighting its progress in developing novel treatments for kidney disease. The company’s lead asset, oxylanthanum carbonate (OLC), is under review by the FDA for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. The New Drug Application (NDA) for OLC was resubmitted following resolution of manufacturing-related issues, and the FDA has set a Prescription Drug User Fee Act (PDUFA) date of June 29, 2026. Unicycive reports an expanded market opportunity for OLC, citing recent developments in the reimbursement landscape. The presentation also notes that the company’s pipeline includes UNI-494, in development for acute kidney injury and chronic kidney disease. The company states it has a cash runway into 2027 to support its ongoing development and potential commercial activities. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on February 06, 2026, and is solely responsible for the information contained therein.